NCE-1 Intelligence & Market Opportunity

Crenessity

Crinecerfont

Hormonal Therapy

Oral Capsules

Crenessity is used to treat classic congenital adrenal hyperplasia. It is administered together with glucocorticoids to control androgen levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia.

Approval Date

13-Dec-24

NCE-1 Date

13-Dec-28

NCE Date

13-Dec-29

Commercial snapshot

Market performance & projections

Revenue ($M)

301

CAGR (%)

0.3747

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

684

2027

798

2028

922

2029

1075

2030

1217

2031

1377

2032

1513

Molecule profile

Details & specifications

Molecule

Crinecerfont

Innovator

NEUROCRINE BIOSCIENCES INC

Dosage Form

Oral Capsules

Strength

25 mg, 50 mg and 100 mg

Therapeutic Category

Hormonal Therapy

Usage

To treat classic congenital adrenal hyperplasia

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.